Innate lymphoid cells (ILCs) are innate-like lymphocytes that contribute to tissue homeostasis, barrier immunity, inflammation, and host defense. In metabolic syndrome (MetS), a condition estimated to affect more than 1.5 billion adults worldwide, dietary patterns and gut microbial metabolites are increasingly recognized as regulators of immune and metabolic dysfunction [1-8]. This review critically summarizes mainly experimental and preclinical evidence, with selected human observations where available, linking dietary components, gut microbiota-derived metabolites, and ILC subsets to obesity, insulin resistance, type 2 diabetes mellitus (T2DM), and related metabolic complications. Current evidence suggests that dietary fibers, short-chain fatty acids, lipids, vitamins, and fermented foods can modulate ILC1, ILC2, and ILC3 responses in a context-dependent manner. However, most mechanistic data derive from mouse models, and direct translation to human MetS remains limited. Through integrating diet-microbiota interactions, ILC subset biology, and metabolic inflammation, this review highlights candidate pathways and biomarkers that may guide future therapeutic studies rather than established clinical interventions.
No takes yet. Share an insight, caveat, or question.
Aoki et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: